Alnylam Pharmaceuticals (ALNY) Posts Earnings Results, Misses Expectations By $0.10 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) released its earnings results on Thursday. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10), Bloomberg Earnings reports. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $37.90 million during the quarter, compared to the consensus estimate of $19.31 million. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. The firm’s revenue for the quarter was up 116.6% compared to the same quarter last year.

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $116.32 on Friday. Alnylam Pharmaceuticals has a 1 year low of $44.50 and a 1 year high of $147.63. The company has a market cap of $12,005.21, a P/E ratio of -22.16 and a beta of 2.69. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

In related news, SVP Laurie Keating sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the transaction, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at $5,639,435. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Maraganore sold 73,415 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total transaction of $9,610,023.50. Following the transaction, the chief executive officer now directly owns 223,125 shares in the company, valued at $29,207,062.50. The disclosure for this sale can be found here. Insiders have sold 220,409 shares of company stock worth $28,667,017 over the last ninety days. 4.30% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. Prudential Financial Inc. grew its position in Alnylam Pharmaceuticals by 4.8% during the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 200 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Alnylam Pharmaceuticals by 6.7% during the second quarter. PNC Financial Services Group Inc. now owns 9,270 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 585 shares in the last quarter. Northern Trust Corp grew its position in Alnylam Pharmaceuticals by 5.0% during the second quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock valued at $30,072,000 after purchasing an additional 17,862 shares in the last quarter. M&T Bank Corp purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $331,000. Finally, Suntrust Banks Inc. purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $320,000. 88.39% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently commented on ALNY shares. FBR & Co started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, October 30th. They issued a “buy” rating and a $150.00 target price on the stock. B. Riley started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They issued a “buy” rating and a $240.00 target price on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $14.71 target price (down from $188.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, November 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $152.00 target price (up from $125.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Finally, Cowen reiterated an “outperform” rating and issued a $151.00 target price (up from $117.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $123.93.

WARNING: “Alnylam Pharmaceuticals (ALNY) Posts Earnings Results, Misses Expectations By $0.10 EPS” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2018/02/08/alnylam-pharmaceuticals-alny-releases-earnings-results-misses-expectations-by-0-45-eps.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply